Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe

BACKGROUND: Oral squamous cell carcinoma (OSCC) has been one of the most malignant cancers in head and neck region. Anlotinib is a tyrosine kinase inhibitor targeting several receptors such as vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-der...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Zhaoming, Liao, Wei, Wei, Wei, Zhong, Guihua, He, Chao, Zhang, Hongbo, Liu, Qiaodan, Xu, Xiwei, Liang, Jun, Liu, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796634/
https://www.ncbi.nlm.nih.gov/pubmed/33422069
http://dx.doi.org/10.1186/s12935-020-01721-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796634/
https://www.ncbi.nlm.nih.gov/pubmed/33422069
http://dx.doi.org/10.1186/s12935-020-01721-x

Ejemplares similares